Latest:
Scientific articles 

New Drug Targets for Tuberculosis in Nature Publications

الموقع الالكتروني

Professor Dr. Hassan Mahmoud Moussa
Mycobacterium tuberculosis continues to prolong treatment duration and increase relapse rates, particularly with MDR and XDR strains. Therefore, Nature publications, including Nature, Nature Communications, Communications Biology, Scientific Reports, and Nature Reviews Drug Discovery, have highlighted a wave of new drug targets that attack vital bottlenecks beyond the classic targets, such as mycolic acid synthesis via InhA.

The central idea is to target highly fragile physiological functions that affect bacterial survival within the host and demonstrate high synergistic potential with existing drugs or clinical candidates.

  1. Cell Wall: Targets Beyond the Traditional Concept

The mycobacterial cell wall is a complex, highly lipid-rich shield. Therefore, new targets have emerged within the pathways for the synthesis or transport of cell wall components.

DprE1 is a pivotal enzyme in the arabinan synthesis pathway within arabinogalactan and lipoarabinomanan, making it an attractive target because its inhibition disrupts cell wall integrity and increases cell sensitivity to environmental stresses. Nature publications, including Scientific Reports, address the development and evaluation of novel DprE1 inhibitors, providing mechanistic and chemical support for the idea that DprE1 is a pharmacologically viable target and a recurring theme in recent discovery campaigns. (Nature) MmpL3 is a key transporter for trehalose monomycolate, a central step in cell wall distribution of mycolic acids. The importance of MmpL3 lies not only in its genetic necessity but also in its cross-linking with several independent chemical structures, meaning that bacteria exhibit pharmacological susceptibility at this node. High-profile evidence has been provided that indoleamides target MmpL3 and exhibit efficacy in mice, with resistance associated with mutations in mmpL3, a strong pattern for establishing an intracellular target. (Nature)
Pks13 is a key enzyme in the terminal steps of mycolic acid synthesis and is considered a more recent “wall target” compared to the InhA pathway. A study published in Nature demonstrated that an anti-tuberculosis compound based on SuFEx chemistry irreversibly inhibits Pks13, a significant concept because it increases the potential for potent bacterial killing through the definitive disruption of a key function. Nature Reviews Drug Discovery also supported the idea that disrupting the FadD32-Pks13 axis represents a promising avenue for overcoming conventional drug resistance. (Nature)
KasA is a FAS-II enzyme essential for lipid chain elongation in the mycolic acid pathway. A Nature Communications publication identified KasA as a cellular target for an anti-tuberculosis compound, a classic example of how to move from observing phenotypic activity to identifying a pharmacologically scalable molecular target. (Nature)

  1. Respiration and Energy Production: Targets of Mycobacteria’s “Last Breath”
    Targeting the respiratory pathway has become a major trend, as mycobacteria possess respiratory flexibility that allows them to circumvent certain inhibitors. This highlights the value of “combined targeting.”

QcrB inhibition by cytochrome bc1 complex
This target is central to the action of drugs and filters that act as inhibitors of the bc1 molecule. The role of bc1 inhibitors in the future of tuberculosis treatment has been discussed, including the importance of understanding synergistic and resistance mechanisms, since inhibiting bc1 alone may not be sufficient due to circumvention pathways. (Nature)
Cytochrome bd inhibition as an alternative pathway
It has been clearly shown that inhibiting cytochrome bd can enhance the lethal efficacy of a bc1 inhibitor such as Q203, because the bacterium uses bd as a circumvention mechanism to maintain electron flow. This translates practically to the concept of “closing all the exits,” i.e., bc1 combined with bd to induce an irreversible energy breakdown. (Nature)

The effectiveness of respiratory inhibitors can also vary depending on the available carbon source, an important factor when interpreting laboratory results and relating them to the body’s environment. Scientific Reports highlighted that carbon metabolism can modify the effectiveness of respiratory drugs, meaning that the design of combination therapies must consider the nutritional conditions within the lesions. (Nature)
3-Nucleotide Metabolism: PurF as a Target for the “First Step in Purine Synthesis”
One of the most significant recent additions to Nature is the targeting of PurF, the first enzyme in the purine synthesis pathway. A 2025 Nature publication presents a first-of-its-kind inhibitor targeting PurF in mycobacteria, with nano-killing potency and high target selectivity—properties that make this pathway attractive because it disrupts the bacterium’s ability to synthesize DNA and RNA building blocks under host stress. (Nature)

  1. Inhibition of Tuberculosis Protein Homeostasis: The Clp System as a Vulnerable Lifeguard
    The Clp system, which includes ClpP1P2 with ATPases such as ClpC1 and ClpX, controls protein quality and is critically important in bacteria subjected to oxidative stress, nutrient deficiencies, and environmental changes within phagocytes. Nature Communications has presented a cryo-EM structure of Clp complexes in mycobacteria bound to bortezomib, demonstrating how a drug known for cancer can bind to Clp complexes and affect protein homeostasis. These findings support the idea of ​​repurposing, or even repurposing, chemistries to construct selective inhibitors against mycobacterial Clp. (Nature)

Communications Biology has also highlighted mutations in ClpC1 or ClpX that are relevant to the concept of drug targeting of the Clp system, further validating this target in the context of resistance evolution. (Nature)

  1. Coenzyme Metabolism: CoaBC as a Promising Allosteric Target

The coenzyme A synthesis pathway is a crucial area of ​​focus, and Nature Communications has presented important work on CoaBC, identifying inhibitors that bind to a hidden allosteric site, along with structural and regulatory characterization of the enzyme.

Allostericity is valuable here because it may open the door to selectivity and reduced toxicity, while maintaining lethal potency when the intracellular target is depleted. (Nature)

  1. DNA Repair: Ku as an Unconventional Target
    In the context of stress resistance, DNA repair may offer mycobacteria a chance to survive drug attacks. Nature Communications has published structural work on the Ku protein in mycobacteria and its role in DNA repair, proposing it as a potential target.

Such unconventional targets are important because they may not exhibit cross-resistance with current drug lines and could be used to reduce the emergence of resistance when combined with cell wall or respiration inhibitors. (Nature)

Applied Summary: How Targets Translate into Treatment Strategies
Within the framework of Nature, the overall picture is not “one target, one drug,” but rather a network of targets exploited through:

  1. Direct cell wall killing, such as DprE1, MmpL3, Pks13, and KasA.
  2. Energy suppression via QcrB and cytochrome bd, with sensitivity to the metabolic context.
  3. Suppression of biosynthesis via PurF and nucleotide pathways.
  4. Disruption of protein management via Clp.
  5. Inactivation of biohelpers, such as CoaBC. 6. Weakening DNA repair as a lever against tolerance and survival.

From this perspective, the new targets for tuberculosis bacteria in the Nature publications represent a shift from “wall-only manufacturing” to “multi-axial breakdown engineering”—wall, energy, nucleotides, protein homeostasis—which increases the likelihood that future therapeutic regimens will be shorter in duration, more lethal, and less prone to generating resistance.
References
1) Lamprecht DA, et al. (2025). Targeting de novo purine biosynthesis for tuberculosis. Nature.
https://www.nature.com/articles/s41586-025-09177-7
2) Krieger IV, et al. (2025). SuFEx-based antitubercular compound irreversibly inhibits Pks13. Nature.
https://www.nature.com/articles/s41586-025-09286-3
3) Lun S, et al. (2013). Indoleamides are active against drug-resistant tuberculosis by targeting the mycolic acid transporter MmpL3. Nature Communications.
https://www.nature.com/articles/ncomms3907
4) Degiacomi G, et al. (2017). Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis. Scientific Reports.
https://www.nature.com/articles/srep43495
5) Dash S, et al. (2024). Identification of DprE1 inhibitors for tuberculosis through in-silico approaches. Scientific Reports.
https://www.nature.com/articles/s41598-024-61901-x
6) Richter A, et al. (2018). Novel insight into reactions of benzothiazinones with Mycobacterium tuberculosis DprE1. Scientific Reports.
https://www.nature.com/articles/s41598-018-31316-6
7) Römpp A, et al. (2025). The clinical-stage drug BTZ-043 accumulates in murine tissues. Nature Communications.
https://www.nature.com/articles/s41467-025-56146-9
8) Aguilar-Pérez C, et al. (2025). The role of cytochrome bc1 inhibitors in future tuberculosis therapy. Nature Communications.
https://www.nature.com/articles/s41467-025-64427-6
9) Lu P, et al. (2018). Inhibition of cytochrome bd enhances bactericidal activity of Q203. Scientific Reports.
https://www.nature.com/articles/s41598-018-20989-8
10) Kalia NP, et al. (2019). Carbon metabolism modulates efficacy of drugs targeting the respiratory chain (QcrB inhibitors). Scientific Reports.
https://www.nature.com/articles/s41598-019-44887-9
11) Abrahams KA, et al. (2016). Identification of KasA as the cellular target of an anti-tubercular compound. Nature Communications.
https://www.nature.com/articles/ncomms12581
12) Zhou B, et al. (2025). Structural insights into bortezomib binding to Mtb Clp protease complexes. Nature Communications.
https://www.nature.com/articles/s41467-025-58410-4
13) Gao Y, et al. (2025). Mutations in ClpC1 or ClpX subunit of caseinolytic protease in mycobacteria. Communications Biology.
https://www.nature.com/articles/s42003-025-08646-z
14) Mendes V, et al. (2021). Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site. Nature Communications.
https://www.nature.com/articles/s41467-020-20224-x
15) Zahid S, et al. (2025). Oligomerisation of Ku from Mycobacterium tuberculosis, DNA repair relevance and target potential. Nature Communications.
https://www.nature.com/articles/s41467-025-65609-y
16) Harrison C. (2013). Hitting the tuberculosis wall. Nature Reviews Drug Discovery.
https://www.nature.com/articles/nrd4080
17) Crunkhorn S. (2017). New routes to tuberculosis treatment. Nature Reviews Drug Discovery.
https://www.nature.com/articles/nrd.2017.156